The FDA drug database lists a supplement dated 8 October 2026 to the biologics licence application for atezolizumab, held by Genentech. The record names only the application and the company, and gives no detail of what changed.
A supplement may cover a labelling change, a manufacturing change or a new use; this record does not say which. It is not by itself an approval of a new indication or a safety communication. For prescribers, nothing about how atezolizumab is used follows from the entry, and in India the position is set by CDSCO labelling, which this record does not address.
- The record does not state whether the supplement concerns labelling, manufacturing or a new use
- Check the current prescribing information before relying on any change
- In India, CDSCO-approved labelling and availability apply
- No change to practice follows from this entry alone
Why it matters
A supplement entry is easily mistaken for a new approval, and the record carries no detail.
Don't overread it
A licence supplement is not a new indication, and this entry gives no safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free